Cost-effectiveness of partially-hydrolyzed formula for prevention of atopic dermatitis in Australia

John Su, Susan Prescott, John Sinn, Mimi Tang, Peter Smith, Ralf G. Heine, Jörg Spieldenner, Michael Iskedjian

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)

Abstract

Objective: To perform an economic evaluation of a specific brand of partially hydrolyzed infant formula (PHF-W) in the prevention of atopic dermatitis (AD) among Australian infants. Methods: A cost-effectiveness analysis was undertaken from the perspectives of the Department of Health and Aging (DHA), of the family of the affected subject and of society as a whole in Australia, based on a decisionanalytic model following a hypothetical representative cohort of Australian newborns who are not exclusively breastfed and who have a familial history of allergic disease (i.e., are deemed 'at risk'). Costs, consequences, and incremental cost-effectiveness ratios (ICER) were calculated for PHF-W vs standard cow's milk based infant formula (SF), and, in a secondary analysis, vs extensively hydrolyzed infant formula (EHF-Whey), when the latter was used for the prevention of AD. Results: From a representative starting cohort of 87,724 'at risk' newborns in Australia in 2009, the expected ICERs for PHF-W vs SF were AU$496 from the perspective of the DHA and savings of AUD1739 and AU$1243 from the family and societal perspectives, respectively. When compared to EHF-Whey, PHF-W was associated with savings for the cohort of AU$5,183,474 and AU$6,736,513 from the DHA and societal perspectives. Limitations: The generalizability and transferability of results to other settings, populations, or brands of infant formula should be made with caution. Whenever possible, a conservative approach directing bias against PHF-W rather than its comparators was applied in the base case analysis. Assumptions were verified in one-way and probabilistic sensitivity analyses, which confirmed the robustness of the model. Conclusions: PHF-W appears to be cost-effective when compared to SF from the DHA perspective, dominant over SF from the other perspectives, and dominant over EHF-Whey from all perspectives, in the prevention of AD in 'at risk' infants not exclusively breastfed, in Australia.

Original languageEnglish
Pages (from-to)1064-1077
Number of pages14
JournalJournal of Medical Economics
Volume15
Issue number6
DOIs
Publication statusPublished - 2012

Keywords

  • Allergy
  • Atopic dermatitis
  • Cost-effectiveness analysis
  • Economic
  • Infant formula
  • Infant nutrition
  • Prevention

Cite this